What happened in optometry this week: February 12 - February 16
Catch up on what happened in optometry during the week of February 12-February 16.
Catch up with what Optometry Times shared this week:
FDA grants SightGlass Vision Breakthrough Device designation for DOT spectacle lenses
By Emily Kaiser Maharjan, Assistant Managing Editor
The FDA has granted Breakthrough Device designation for SightGlass Vision's Diffusion Optics Technology (DOT) spectacles lenses, which are under investigation for the slowing of myopia in children.
G360 2024: Gene therapy for glaucoma: Great potential but a long way to fruition
By Lynda Charters
Terri Pickering, MD, clinical instructor, California Pacific Medical Center, and board of directors member, Glaucoma Research Foundation, San Francisco, reported that there is increasing evidence for the efficacy of various experimental glaucoma gene therapies.
Capitol Hill inquires about abusive marketplace tactics in vision, dental coverage
By Jordana Joy, Associate Editor
The push for overseeing fair eye care coverage on Capitol Hill continues with a recent inquiry into abusive marketplace tactics that could be used by specialty plans for vision and dental coverage.
Pharmacologic weight loss for diabetes management: The good, the bad, and the ugly
By A. Paul Chous, MA, OD, FAAO
Risk of type 2 diabetes (T2D) has long been associated with overweight and obesity. Recently, a systematic review and dose-response meta-analysis of 216 cohort studies of more than 28 million subjects showed a 72% increased relative risk for T2D for each 5-point increase in body mass index and 255% increased risk for a 10% increase in body adiposity index, an amalgam of the ratio of hip circumference to body height defined by the formula hip circumference in centimeters/height in meters x (height in meters)1.5 – 18.1,2
Sylentis misses end point in Phase 3 SYL1001_V trial for dry eye caused by Sjögren syndrome
By Jordana Joy, Associate Editor
Results from the Phase 3 SYL10111_V (tivanisiran) indicate that the drug’s primary end point to evaluate the signs and symptoms of dry eye disease caused by Sjögren syndrome was not met. The trial, sponsored by PharmaMar subsidiary Sylentis,1 measured the change of baseline in corneal fluorescein staining, measured on a scale from 0 to 3, and dry eye symptoms, measured on a scale from 0 to 100, brought on by Sjögren syndrome.
